A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma Clinical Trial

Official title:

A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03088878
• Other study ID #: CIRM-0001 (CIRLL)
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: January 3, 2018
• Est. completion date: August 30, 2024

Study information

• Verified date: September 2023
• Source: Oncternal Therapeutics, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.

Description:

This is a Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab (INN:zilovertamab), when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. The Phase 1b will be conducted in two parts (Part 1 and Part 2). Part 1 is a dose-finding evaluation of the sequential administration of cirmtuzumab monotherapy followed by cirmtuzumab and ibrutinib combination therapy in chronic lymphocytic leukemia /small lymphocytic leukemia (CLL/SLL), previously treated mantle cell lymphoma (MCL) subjects that are BTKI naiive or have received a prior Bruton tyrosine kinase (BTK) inhibitor therapy, unless they demonstrated primary or acquired resistance to BTKi. Up to 48 subjects will be enrolled in Part 1 to determine the recommended dosing regimen (RDR). In Part 2, up to 60 subjects (CLL/SLL, MCL and MZL (marginal zone lymphoma) will be enrolled to further evaluate the safety and pharmacology of the cirmtuzumab and ibrutinib combination given at the RDR determined in Part 1 of the study. MZL subjects that have been previously treated and have relapsed after or progressed during at least one prior anti-CD20 -based therapy will be evaluated. In the Phase 2 (Part 3) portion of the study, approximately 30 subjects with CLL/SLL who may have received minimal prior BTK inhibitor therapy will be randomized to either Arm 1 (cirmtuzumab and ibrutinib) at the RDR or Arm 2 (ibrutinib alone) to evaluate the clinical activity and safety of the two arms.

Other known NCT identifiers

• NCT03420183

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 102
• Est. completion date: August 30, 2024
• Est. primary completion date: August 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Men and women of age =18 years.

2. ECOG performance status of 0, 1, or 2

3. Histological diagnosis of CLL/SLL, MCL or MZL (including splenic,nodal and extranodal subtypes) as documented in medical records (pathology reports and slides or blocks should be available for review or additional testing).

4. MCL has been previously treated and has relapsed after or progressed during prior therapy. CLL/SLL may have been previously treated or are treatment naïve but now require therapy. MZL has been previously treated and has relapsed after or progressed during at least one prior anti-CD20 -based therapy

5. A medically appropriate candidate for ibrutinib treatment (based on the judgement of the clinical investigator).

6. Patients who have received prior BTK inhibitor therapy are eligible, unless they demonstrated primary or acquired resistance to a BTK inhibitor or experienced a serious or severe adverse event attributed to BTK inhibitor therapy.

7. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of =1 non-biopsied, non-irradiated lesion that measures >1.5 cm in the longest dimension [LD] and =1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]).

8. Current medical need for therapy due to disease-related symptoms, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive disease.

9. Completion of all previous therapy (including any Bcl-2 or PI3K inhibitor therapy, surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer =1 week (or =3 half-lives of the previous drug) before the start of study therapy.

10. All acute toxic effects of any prior antitumor therapy resolved to Grade =1 before the start of study therapy (with the exceptions of alopecia, or neurotoxicity [Grade 1 or 2 permitted], or selected laboratory parameters [Grade 1 or Grade 2 permitted with exceptions as noted below]).

11. Adequate bone marrow function:

1. Absolute neutrophil count (ANC) =1.0 × 109/L.

2. Platelet count =50 × 109/L.

3. Hemoglobin =8.0 g/dL maintained for =1 week from any prior transfusion.

12. Adequate hepatic profile:

1. Serum alanine aminotransferase (ALT) =3 × upper limit of normal (ULN).

2. Serum aspartate aminotransferase (AST) =3 × ULN.

3. Serum bilirubin =1.5 × ULN unless elevated due to Gilbert syndrome.

13. Adequate renal function:

1. Estimated creatinine clearance (eClCR) >30 mL/minute (with eClCR to be calculated by the Cockcroft-Gault formula [see Appendix 12.2]), or

2. Measured creatinine clearance >30 mL/minute (as assessed with a 24-hour urine collection).

14. Adequate coagulation profile:

1. Prothrombin time (PT) =1.5 × ULN.

2. Activated partial thromboplastin time (aPTT) =1.5 × ULN.

15. Negative viral serology:

1. Negative human immunodeficiency virus (HIV) antibody.

2. Negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) antibody or undetectable hepatitis B (HBV) deoxyribonucleic acid (DNA) by quantitative polymerase chain reaction (PCR) testing.

3. Negative hepatitis C virus (HCV) antibody or negative HCV RNA by quantitative PCR.

16. For female patients of childbearing potential, a negative urine or serum pregnancy test prior to the start of study therapy.

17. For female patients of childbearing potential, willingness to use a highly effective method of contraception from the start of the screening period until =3 months after the last dose of cirmtuzumab and =1 month after the last dose of ibrutinib, whichever is later. Note: A female patient is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone [FSH] levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [ßHCG]); or is menopausal (age =50 years with amenorrhea for =6 months).

18. For male patients who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use an effective method of contraception from the start of study therapy until =3 months after the last dose of cirmtuzumab and =3 months after the last dose of ibrutinib, whichever is later and to refrain from sperm donation from the start of study therapy until =3 months after administration of the final dose of either of the study drugs. Note: A male patient is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.

19. In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the patient's cancer.

20. Willingness and ability of the patient to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.

21. Evidence of a personally signed informed consent indicating that the patient is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

Exclusion Criteria:

1. Known histological transformation to an aggressive lymphoma (ie, Richter transformation).

2. Known central nervous system malignancy.

3. Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.

4. Significant cardiovascular disease (eg, myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to start of study therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure; or uncontrolled Grade =3 hypertension (diastolic blood pressure =100 mmHg or systolic blood pressure =160 mmHg) despite antihypertensive therapy.

5. Significant screening ECG abnormalities, including unstable cardiac arrhythmia requiring medication, atrial fibrillation/flutter, left bundle branch block, 2nd-degree atrioventricular (AV) block type II, 3rd-degree AV block, or Grade =2 bradycardia.

6. Gastrointestinal disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs.

7. Contraindication for ibrutinib use because of bleeding diathesis.

8. Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of study therapy. Note: Patients with localized fungal infections of skin or nails are not precluded from participation.

9. In patients with prior hematopoietic progenitor cell transplantation, evidence of ongoing graft-versus-host disease (GVHD).

10. Pregnancy or breastfeeding.

11. Major surgery within 4 weeks before the start of study therapy.

12. Prior solid organ transplantation.

13. Prior anti-ROR1 therapy within 12 weeks prior to the start of study therapy.

14. Use of a moderate or strong inhibitor or inducer of cytochrome P450 (CYP) 3A4 within 7 days prior to the expected start of ibrutinib therapy.

15. Concurrent participation in another therapeutic or imaging clinical trial.

16. Any illness, medical condition, organ system dysfunction, or social situation, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a subject's ability to provide informed consent, adversely affect the subject's ability to cooperate and participate in the study, or compromise the interpretation of study results.

Related Conditions & MeSH terms

• B-cell Chronic Lymphocytic Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphoma
• Lymphoma, B-Cell, Marginal Zone
• Lymphoma, Mantle-Cell
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Intervention

Drug:
• Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
Participants will receive escalating doses of cirmtuzumab (2-16 mg/kg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily, starting at week 4.
• Cirmtuzumab (300mg) plus Ibrutinib
Participants will receive cirmtuzumab (300 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
• Cirmtuzumab (600 mg) plus ibrutinib
Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
• Cirmtuzumab (RDR) plus ibrutinib
Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily
• Cirmtuzumab plus ibrutinib
Arm A: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
• Ibrutinib alone
Arm B: Participants will receive ibrutinib (420 mg) orally once daily

Locations

Country	Name	City	State
United States	Winship Cancer Institute of Emory University	Atlanta	Georgia
United States	The Christ Hospital Lindner Research Center	Cincinnati	Ohio
United States	City of Hope (City of Hope National Medical Center, City of Hope Medical Center)	Duarte	California
United States	Hackensack Meridian Health, John Theurer Cancer Center	Hackensack	New Jersey
United States	MD Anderson Cancer Center	Houston	Texas
United States	Sanford Stem Cell Clinical Center at UCSD	La Jolla	California
United States	Yale Cancer Center	New Haven	Connecticut
United States	Northwell Health	New Hyde Park	New York
United States	Louisiana State University Health New Orleans (NCI Community Oncology Research Program)	New Orleans	Louisiana
United States	Columbia University Medical Center	New York	New York
United States	Manhattan Hematology Oncology Research Foundation, Inc.	New York	New York
United States	UC Davis Comprehensive Cancer Center	Sacramento	California

Sponsors (4)

Lead Sponsor	Collaborator
Oncternal Therapeutics, Inc	California Institute for Regenerative Medicine (CIRM), Pharmacyclics LLC., University of California, San Diego

Country where clinical trial is conducted

United States, 

References & Publications (2)

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Espanol de Medula Osea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. — View Citation

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1:To determine the Recommended dosing regimen (RDR) of cirmtuzumab within the tested dose range in combination of ibrutinib		From first dose of study drug to completion of study drug treatment and have been followed for > 30 days
Primary	Part 2: To determine the Recommended dosing regimen (RDR) of cirmtuzumab in combination with ibrutinib		From first dose of study drug to completion of study drug treatment and have been followed for > 30 days
Primary	Parts 1-2: Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v4.03	Defined as type, frequency, severity, timing of onset, duration, and relationship to study drugs of any treatment-emergent adverse events (TEAEs); SAEs; or AEs leading to interruption, modification, or discontinuation of study treatment	From first dose of study drug to 30 days after the last dose of study drug or 72 weeks after accrual of the final subject
Primary	Parts 1-3: To evaluate Complete Response Rate	Defined as the proportion of subjects that achieve CR for those with CLL/SLL; and the achievement of a CR for those with MCL or MZL	From randomization to end of follow up or 72 weeks after accrual of the final subject
Primary	Parts 1-3: To evaluate Overall Response	Defined as achievement of complete response (CR), complete response with incomplete blood count recovery (CRi), partial response (PR), or partial response with lymphocytosis (PR-L) for those with CLL/SLL; and the achievement of a CR or PR for those with MCL or MZL.	From randomization to end of follow up or 72 weeks after accrual of the final subject
Secondary	Part 3: Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v4.03	Defined as type, frequency, severity, timing of onset, duration, and relationship to study drugs of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign abnormalities; adverse electrocardiogram (ECG) findings; SAEs; or AEs leading to interruption, modification, or discontinuation of study treatment	From first dose of study drug to 30 days after the last dose of study drug or 72 weeks after accrual of the final subject
Secondary	Parts 1-2: Area under the serum concentration-time curve [AUC]	To determine the pharmacokinetic profile of cirmtuzumab alone and in combination with ibrutinib	From first dose of study drug to 30 days after the last dose of study drug
Secondary	Parts 1-3: Changes in ROR1 cell surface expression and receptor occupancy	To determine the effects of cirmtuzumab and cirmtuzumab + ibrutinib on exploratory biomarkers	From first dose of study drug to completion of study drug treatment and have been followed for > 12 weeks
Secondary	Parts 1-3: To evaluate the Immunogenicity	Immunogenicity as measured by neutralizing anti-drug antibodies (NAbs) to CIRM over time in seronegative and seropositive participants (based on central lab test)	From randomization to 30 days after the last dose of study drug or 72 weeks after accrual of the final subject
Secondary	Parts 1-3:To evaluate Overall Response (OR)	Defined as achievement of complete response (CR), complete response with incomplete blood count recovery (CRi), partial response (PR), or partial response with lymphocytosis (PR-L) for those with CLL/SLL; and the achievement of a CR or PR for those with MCL or MZL	From randomization to 30 days after the last dose of study drug or 72 weeks after accrual of the final subject
Secondary	Parts 1, 2, 3:To evaluate Complete Response (CR)	Defined as achievement of CR or CRi for those with CLL/SLL; and the achievement of a CR for those with MCL or MZL	From randomization to 30 days after the last dose of study drug or 72 weeks after accrual of the final subject
Secondary	Parts 1-3:To evaluate percent change in tumor dimensions	Defined as the best (most negative) percent change from baseline in the sum of the products of the diameters (SPD) of index lesions	From randomization to end of follow up or 72 weeks after accrual of the final subject
Secondary	Parts 1-3: To evaluate Time to Response (TTR)	Defined as the interval from the start of study therapy to the first documentation of an objective response	From randomization to end of follow up or 72 weeks after accrual of the final subject
Secondary	Parts 1-3:To evaluate Duration of Response (DOR)	Defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause	From randomization to end of follow up or 72 weeks after accrual of the final subject
Secondary	Parts 1-3: To evaluate Progression-free Survival (PFS)	Defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause	From randomization to end of follow up or 72 weeks after accrual of the final subject
Secondary	Parts 1-3: To evaluate Time to Progression (TTP)	Defined as the time from the start of study therapy until objective tumor progression; TTP does not include deaths	From randomization to end of follow up or 72 weeks after accrual of the final subject
Secondary	Parts 1-3: To evaluate Time to Treatment Failure (TTF)	Defined as the interval from start of study therapy to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause	From randomization to end of follow up or 72 weeks after accrual of the final subject
Secondary	Parts 1-3:To evaluate Time to Next Treatment (TNT)	Defined as the interval from start of study therapy to the earliest of the start of a new regimen for CLL/SLL, MCL or MZL due to study treatment failure	From randomization to end of follow up or 72 weeks after accrual of the final subject
Secondary	Parts 1-3: To evaluate Overall Survival (OS)	Defined as the interval from the start of study therapy to death from any cause	From randomization to end of follow up or 72 weeks after accrual of the final subject